- Hepatic vascular microenvironment, notably liver sinusoidal endothelial cells, acts as a regulatory hub driving MAFLD progression alongside metabolic dysfunction.
- Endothelial metabolic reprogramming, reduced nitric oxide bioavailability and sinusoidal microcirculatory impairment promote lipotoxicity, immune activation and tissue hypoxia.
- A stage-associated framework links early endothelial stress, immune endothelial amplification and fibrotic remodelling, highlighting vascular targets for therapeutic intervention.
Front Endocrinol (Lausanne). 2026 Oct 30;17:1916728. doi: 10.3389/fendo.2026.1916728. eCollection 2026.
ABSTRACT
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the leading cause of chronic liver disease worldwide and is increasingly recognized as a multisystem disorder driven by intertwined metabolic and vascular dysfunction. Beyond the classical features of steatosis, inflammation, and fibrosis, emerging evidence suggests that disruption of the hepatic vascular microenvironment may contribute to MAFLD progression, although its temporal relationship with metabolic injury requires further validation. The liver sinusoid constitutes a highly specialized vascular niche in which liver sinusoidal endothelial cells (LSECs) function as metabolic gatekeepers and mechanosensors, integrating blood flow, shear stress, and nutrient exchange to maintain hepatic homeostasis. In MAFLD, endothelial metabolic reprogramming, reduced nitric oxide bioavailability, and sinusoidal microcirculatory impairment collectively disrupt vascular regulation, thereby promoting lipotoxicity, inflammatory activation, and tissue hypoxia. These processes may be further amplified by multicellular crosstalk, wherein immune cells exacerbate endothelial dysfunction, while hepatic stellate cells (HSCs) promote extracellular matrix deposition, vascular stiffening, and increased sinusoidal resistance. In this review, we synthesize current evidence from a vascular microenvironment perspective and propose a stage-associated conceptual framework encompassing early endothelial stress, immune-endothelial amplification, and fibrotic remodeling. We also discuss emerging therapeutic strategies targeting endothelial metabolism, microcirculatory function, and vascular resistance. By integrating metabolic, inflammatory, and biomechanical processes, this review highlights the hepatic microvasculature as a candidate regulatory hub warranting prospective evaluation as a translational target in MAFLD.
PMID:43032060 | PMC:PMC13760564 | DOI:10.3389/fendo.2026.1916728
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

